Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-02-27

FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

View source ↗

Summary

FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc. This action updates the product's regulatory status with the FD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EGRIFTA WR (TESAMORELIN)

Snippet

SUPPL AP for EGRIFTA WR (TESAMORELIN)